PRC2 loss drives MPNST metastasis and matrix remodeling
Authors:
- Qierra R. BrockmanQBQierra R. Brockman
- Amanda SchererASAmanda Scherer
- Gavin R. McGivneyGMGavin R. McGivney
- Wade R. GutierrezWGWade R. Gutierrez
- Andrew P. VoigtAVAndrew P. Voigt
- Alexandra L. IsaacsonAIAlexandra L. Isaacson
- Emily A. LavertyELEmily A. Laverty
- Grace RoughtonGRGrace Roughton
- Vickie Knepper-AdrianVKVickie Knepper-Adrian
- Benjamin DarbroBDBenjamin Darbro
- Munir R. TanasMTMunir R. Tanas
- Christopher S. StippCSChristopher S. Stipp
Open Access
- 24 October 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (20)
Abstract
The histone methyltransferase PRC2 plays a complex role in cancer. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with frequent loss-of-function mutations in PRC2 that are associated with poor outcome. Here, we identify a critical role for PRC2 loss in driving MPNST metastasis. PRC2-dependent metastatic phenotypes included increased collagen-dependent invasion, upregulation of matrix-remodeling enzymes, and elevated lung metastasis in orthotopic mouse models. Furthermore, clinical sample analysis determined that PRC2 loss correlated with metastatic disease, increased fibrosis, and decreased survival in patients with MPNSTs. These results may have broad implications for PRC2 function across multiple cancers and provide a strong rationale for investigating potential therapies targeting ECM-remodeling enzymes and tumor fibrosis to improve outcomes in patients with MPNSTs.Keywords
Funding Information
- American Cancer Society (Research Scholar Award (RDD))
- U.S. Department of Defense (NF170067,(RDD))
- National Institutes of Health (P30 CA086862,(UIowa))
This publication has 58 references indexed in Scilit:
- NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK InhibitionMolecular Cancer Therapeutics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer CellsPLOS ONE, 2012
- First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group studyAnnals of Oncology, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Collective cell migration in morphogenesis, regeneration and cancerNature Reviews Molecular Cell Biology, 2009
- Imaging Intratumoral Convection: Pressure-Dependent Enhancement in Chemotherapeutic Delivery to Solid TumorsClinical Cancer Research, 2008
- A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer OutcomeCancer Research, 2007
- Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavityOncogene, 2004
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002